Your Blood Pressure Pill May Be Too Strong: the 21,620-Bottle Telmisartan Recall, the 5 Lots, and the Check to Run Tonight
The FDA has listed a Class III recall of 21,620 bottles of telmisartan and amlodipine tablets, 40 milligrams and 5 milligrams, after the telmisartan in five lots may exceed its potency specification. Initiated by Viatris Inc. on October 1, 2026, the recall covers 30-count bottles distributed nationwide; the check is the lot number and expiry date on your bottle.
Key facts
- 21,620 bottles recalled: 30-count bottles of telmisartan 40 mg and amlodipine 5 mg.
- 5 lots affected: 3228113, 3228114, and 3228115 (expiry October 31, 2026); 3228120 and 3228121 (expiry November 30, 2026).
- Recall initiated October 1, 2026, by Viatris Inc.; the tablets were manufactured in India for Mylan Pharmaceuticals Inc. of Morgantown, West Virginia.
- National Drug Code: 0378-1075-93; distribution was nationwide across the United States.
- Class III: the FDA defines a Class III recall as a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
What “superpotent” means here
“Superpotent” is the FDA enforcement-report term for a drug whose active ingredient may be present above its established specification. In this recall the concern is specific: the telmisartan content in these lots may exceed specifications. Telmisartan is an angiotensin II receptor blocker, a medicine that lowers blood pressure by blocking a hormone that narrows blood vessels, while amlodipine is a calcium channel blocker, a medicine that relaxes blood vessels. The recall reason names telmisartan only; it does not say the amlodipine content is out of specification. The FDA has not stated how much extra telmisartan the tablets may contain, so no one should guess a dose from this recall notice.
The 5 lots to check
Match all three identifiers, not just the drug name: the product (telmisartan and amlodipine tablets, 40 mg/5 mg, 30-count bottle), the lot number, and the expiry date. The affected combinations are lot 3228113, lot 3228114, and lot 3228115, each expiring October 31, 2026, and lot 3228120 and lot 3228121, each expiring November 30, 2026. A bottle with a different lot number, a different strength, or a different manufacturer is not part of this recall, even if it contains telmisartan or amlodipine. Keep the bottle until a pharmacist has seen the label, because the lot number is the evidence that decides whether you are affected.
What the extra telmisartan could do
The Class III classification matters: the FDA's judgment is that use of this product is not likely to cause adverse health consequences. That is a classification of the recall, not a guarantee for any individual. Overdose information for this combination warns that too much of the medicine could cause low blood pressure, dizziness, or a rapid heart rate, which is why an unexpected faint, fall, or racing pulse after starting a new bottle deserves a prompt call to a clinician or pharmacist rather than a wait-and-see approach. Do not try to compensate by splitting tablets, skipping doses on your own, or switching to a leftover bottle of a different strength: blood pressure medicines are dosed as a combination, and an abrupt change can carry its own risk.
What to do tonight, in order
First, read the label now: product name, strength, lot number, expiry date, and manufacturer. Second, if your bottle matches one of the five lots, call your pharmacist or prescriber promptly and ask what replacement they will supply and when; pharmacies handle recalled stock routinely and can confirm whether your bottle goes back through them. Third, do not stop the medicine on your own without that advice, because stopping a blood pressure medicine abruptly can be harmful, and a pharmacist can usually arrange a replacement without a gap. Fourth, if you feel faint, dizzy, or notice a racing pulse, seek medical advice the same day and mention the lot number. The same discipline applies to any medicine recall: the label, not the headline, decides whether you are affected, as our guide to a hospital-meter recall that sent correct results to the wrong patients also shows (the StatStrip hospital meter recall).
What this recall is not
This recall does not cover every telmisartan tablet, every amlodipine tablet, or every blood pressure medicine on the market. It covers one product, one strength, one bottle size, five lots, and one manufacturer chain. Nor does a Class III label mean the medicine is “just fine” or that a lawsuit follows automatically: it means the FDA assessed the health risk as unlikely, and any question about harm from a specific bottle is a medical question first, answered from records, the lot, and the prescriber's notes. If a pharmacy makes an error of its own, such as dispensing the wrong drug or dose, that is a different problem with different proof, explained in our guide to pharmacy errors.
Who Benefits From This — and Who Does Not
Who benefits. People holding a 40 mg/5 mg bottle of this exact product benefit most, because a two-minute label check either clears them or gets them a replacement before the next refill. Caregivers who manage a parent's medicines benefit too, since they can check every bottle in the cabinet in one pass. Pharmacists and prescribers benefit from patients who arrive with the lot number in hand, because the conversation becomes a swap, not a search.
Who does not benefit, or for whom this is not enough. People taking a different strength, a different manufacturer, or telmisartan or amlodipine alone gain nothing from this recall check, and should not stop a working medicine because of a headline about another product. People who already feel unwell after a new bottle need medical advice, not a recall article: this guide cannot diagnose a symptom. And anyone hoping this recall alone proves a claim will be disappointed, since the FDA's own classification says adverse consequences are not likely, and proof would need medical records tied to an affected lot. For the contrast with a device recall where the check is a serial number rather than a lot, see the B. Braun dialysis bloodline early alert.
Frequently Asked Questions
- Is my telmisartan recalled?
Only if your bottle is telmisartan and amlodipine tablets, 40 mg/5 mg, in a 30-count bottle from this manufacturer chain, with lot 3228113, 3228114, or 3228115 expiring October 31, 2026, or lot 3228120 or 3228121 expiring November 30, 2026. Any other lot, strength, or manufacturer is not part of this recall. - Who benefits from checking the lot number?
Anyone holding this exact product benefits, because the check takes two minutes and either clears the bottle or starts a replacement. Caregivers checking a parent's cabinet benefit most, since one pass covers every bottle. - Who does not benefit from this recall?
People taking a different strength, a different manufacturer, or either drug alone do not benefit, and should not stop a working medicine because of this recall. People who feel unwell need medical advice, not a recall check. - What should I do if my bottle matches a recalled lot?
Call your pharmacist or prescriber promptly, keep the bottle with its label, and ask what replacement they will supply and when. Do not stop the medicine on your own without that advice, because stopping a blood pressure medicine abruptly can be harmful. - How do I start if I cannot find the lot number?
Start with the pharmacy that filled the prescription: it can usually identify the lot from its dispensing record. Bring the bottle if you still have it, and ask the pharmacist to check the lot and expiry against the five affected combinations. - Does a Class III recall mean the drug is safe?
Class III means the FDA assessed that use of the product is not likely to cause adverse health consequences. It is a recall classification, not a personal guarantee, so unexpected symptoms after a new bottle still deserve a prompt call to a clinician.
For plain-language explainers on recalls, benefits, and money questions, the Problem Solved channel on YouTube is here: Problem Solved channel.
This article is general information only and is not legal, medical, tax, or financial advice. If a product, medicine, or benefit described here affects you, confirm your own situation with the manufacturer, your pharmacist or clinician, or a qualified professional before you act.